Xtandi Off to a Fast Start (MDVN) - Leerink Swann

November 12, 2012 7:23 AM EST Send to a Friend
Get Alerts MDVN Hot Sheet
Price: $119.74 +5.18%

Rating Summary:
    21 Buy, 5 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 12 | Down: 23 | New: 21
Trade MDVN Now!
Join SI Premium – FREE
Leerink Swann reiterated their Outperform rating on Medivation (NASDAQ: MDVN), saying Xtandi appears to be off to a fast start.

The firm comments, "As previously reported by Astellas and in an 8-K by MDVN, US Xtandi sales were $14.1M for the 12 shipping days in the 3Q12. We believe this represents a good start of the commercial launch, though a substantial portion was likely related to stocking and patients rolling over from the EAP. MDVN announced that Phase III clinical trials for Xtandi are being planned, although the indications are in discussion with partner Astellas and will be publicly announced at a later date."

For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.

Shares of Medivation closed at $45.70 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Add Your Comment